GlobeNewswire by notified

Sandoz submits Marketing Authorization Application for proposed biosimilar trastuzumab to EMA

Share
  • Submission is supported by comprehensive package of analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix, Inc.

  • Breast cancer is one of most common types of cancer in women, accounting for over 355,000 new cases in 2020 in Europe alone1

  • Sandoz has been developing and providing oncology medicines for over 30 years, to expand access to and increase affordability of high quality medicines

Basel, December 22, 2021 — Sandoz, a global leader in generic and biosimilar medicines, today announced that it has submitted a Marketing Authorization Application for a proposed biosimilar trastuzumab (150 mg, for intravenous use) developed by EirGenix, Inc. to the European Medicines Agency (EMA).

Trastuzumab is a monoclonal antibody used for the treatment of human epidermal growth factor receptor 2 positive (HER2-positive) breast cancer and metastatic gastric cancers2. Sandoz is seeking approval for the same indications as the reference medicine, based on a comprehensive package that includes analytical, preclinical, and clinical data.

“In 2020, breast cancer accounted for 28.7% of all new cancer cases diagnosed, making it the most frequently occurring cancer and first cause of cancer death among women in Europe1”, said Florian Bieber, Global Head of Biopharmaceuticals Development, Sandoz. “Biosimilars have enormous potential to improve cancer care. Today’s submission is an encouraging step forward in our mission to expand access to advanced biologics treatments to address the evolving needs of patients, healthcare professionals and healthcare systems.”

As part of the license agreement signed in April 2019, EirGenix, Inc. is responsible for development and manufacturing and Sandoz will have the right to commercialize the medicine upon approval in all markets excluding China and Taiwan. On December 20, 2021, Sandoz announced submission of a Biologics License Application for a proposed biosimilar trastuzumab (150 mg) to the US Food and Drug Administration.

Sandoz has been developing and providing oncology medicines for over 30 years. Today, it has more than 50 such medicines, including chemotherapeutics, biologics, hormones and supportive care treatments, for the treatment of a wide range of cancers. The collaboration with EirGenix, Inc. will enable Sandoz to build on its leading generic and biosimilar oncology portfolio to further expand patient access, while contributing to the sustainability of healthcare systems.

Disclaimer 

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that, if approved, such generic or biosimilar products will be approved for all indications included in the reference product’s label. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling its products; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sandoz
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering all major therapeutic areas, accounted for 2020 sales of USD 9.6 billion.

Sandoz on social media:
LinkedIn: https://www.linkedin.com/company/sandoz
Twitter: https://twitter.com/sandoz_global
Facebook: https://www.facebook.com/sandozglobal/
Instagram: https://www.instagram.com/sandozglobal

CEO Richard Saynor on LinkedIn: https://www.linkedin.com/in/richard-saynor/

References

  1. European Commission. Breast Cancer Burden Factsheet. Available from: https://ecis.jrc.ec.europa.eu/pdf/Breast_cancer_factsheet-Dec_2020.pdf [Last accessed: October 2021].
  2. EMA. Herceptin® trastuzumab EPAR. https://www.ema.europa.eu/en/medicines/human/EPAR/herceptin [Last accessed: October 2021].

# # #

Sandoz Global Communications



Chris Lewis
Sandoz Global Communications
+49 174 244 9501 (mobile)
chris.lewis@sandoz.com



Michelle Bauman
Sandoz Global Communications
+1 973 714 8043 (mobile)
michelle.bauman@sandoz.com

Novartis Media Relations
E-mail: media.relations@novartis.com

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

Central North America
Samir Shah +41 61 324 7944 Sloan Simpson +1 862 778 5052
Isabella Zinck +41 61 324 7188
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

IBFD announces a new online transfer pricing qualification to further enhance its tax training offering10.8.2022 10:00:00 CEST | Press release

AMSTERDAM, Aug. 10, 2022 (GLOBE NEWSWIRE) -- IBFD has released the new Advanced Professional Certificate in Transfer Pricing – II (APTCP-II). This market-leading online qualification is aimed at professionals who have a basic understanding about the principles of transfer pricing and wish to enhance their knowledge further in this field. How is the course structured? Starting on 1 November 2022, the six-month programme consists of four courses, each containing several modules that guide you on transfer pricing at an intermediate level in the following areas: Transfer Pricing and Business RestructuringTransfer Pricing ControversyTransfer Pricing and Indirect TaxationOperational Transfer Pricing What skills will you gain? The key skills that you will learn and be able to put into practice are: Be able to determine the transfer pricing aspects of business restructuringsBuild and apply a transfer pricing controversy framework, detect risks and understand various dispute mechanismsDefine a

Release of Marimekko's Half-year Financial report, 1 January–30 June 202210.8.2022 10:00:00 CEST | Press release

Marimekko Corporation, Press release 10 August 2022 at 11.00 a.m. Release of Marimekko's Half-year Financial report, 1 January–30 June 2022 Marimekko Corporation’s Half-year Financial Report 1 January–30 June 2022 will be published on Wednesday 17 August 2022 at 8.00 a.m. EEST. The report and related materials will be available on the company’s website at https://company.marimekko.com/en/investors/ after the publication. A media and investor conference will be held in English on 17 August 2022 at 2.00 p.m. EEST. A live webcast of the conference can be followed at https://marimekko.videosync.fi/q2-2022-results, and a recording of the webcast will be available at the same address later. Questions can be asked during the live webcast in writing. Additional information: Anna Tuominen, Marimekko Communications Tel. +358 40 584 6944 anna.tuominen@marimekko.com DISTRIBUTION: Key media Marimekko is a Finnish lifestyle design company renowned for its original prints and colors. The company’s pr

Aspo Group half-year financial report, January 1 to June 30, 2022: Strong performance continued in Q2; Comparable operating profit reached a record-high EUR 16.0 million10.8.2022 08:30:00 CEST | Press release

Aspo Plc Half-year financial report August 10, 2022, at 9:30 am Aspo Group half-year financial report, January 1 to June 30, 2022 Strong performance continued in Q2: Comparable operating profit reached a record-high EUR 16.0 million Figures from the corresponding period in 2021 are presented in brackets. April–June 2022, continuing operations Aspo’s net sales increased by 16% to EUR 161.4 (139.3) million.Comparable operating profit, at Group total level was EUR 16.0 (9.6) million, and the comparable operating profit rate was 9.7% (6.7%).The comparable operating profit of ESL Shipping was EUR 9.2 (5.4) million, Telko EUR 7.2 (5.5) million, and Leipurin EUR 0.9 (0.3) million.Items affecting the comparability of operating profit totaled EUR -2.4 million at Group total level.Operating profit was EUR 14.8 (9.6) million. The operating profit rate was 9.2% (6.9%).The operating profit of ESL Shipping was EUR 9.0 (5.4) million, Telko EUR 6.8 (5.5) million, and Leipurin EUR 0.4 (0.3) million.Ear

UPDATE ON MBCC ACQUISITION – CLOSING TARGETED FOR H1 202310.8.2022 08:00:00 CEST | Press release

UPDATE ON MBCC ACQUISITION – CLOSING TARGETED FOR H1 2023 The UK Competition and Markets Authority (CMA) has decided to conduct an in-depth examination in the UK market related to Sika’s planned acquisition of MBCC Group. Closing is now targeted for the first half of 2023. The adapted timeline will not impact the strategic attractiveness of the transaction. Guidance for the expected annual synergies remains at CHF 160 – 180 million. In November 2021, Sika signed a definitive agreement to acquire MBCC Group (former BASF Construction Chemicals). The completion of the transaction is subject to regulatory approvals. The UK Competition and Markets Authority (CMA) has decided to conduct an in-depth examination (Phase 2) regarding Sika’s planned acquisition of MBCC Group. This examination will require additional time. The closing of the transaction is therefore now targeted for the first half of 2023 instead of at the end of 2022 as previously announced. Thomas Hasler, Chief Executive Officer

Ahold Delhaize delivers resilient performance in Q2 2022; raises full-year EPS and free cash flow guidance10.8.2022 07:45:00 CEST | Press release

With high levels of inflation, our brands are focused on helping customers efficiently manage their spending. Driven by our €850 million Save For Our Customers cost savings program, our brands are absorbing cost increases for customers, introducing more entry-priced products, expanding high-quality own-brand assortments and delivering personalized value through loyalty programs.Q2 Group net sales increased 6.4% at constant exchange rates to €21.4 billion. At actual exchange rates, net sales grew 15.0%. Q2 net sales accelerated in both regions compared to Q1, growing 7.7% in the U.S. and 4.2% in Europe at constant rates. Increased market share in the majority of markets reflects strong customer loyalty to our locally tailored customer value propositions.Net consumer online sales increased 4.8% at constant exchange rates. Net consumer online sales in grocery increased 11.5% at constant exchange rates, as we continue to invest in creating the leading local omnichannel food experience.Q2 u